|Bid||265.16 x 200|
|Ask||265.39 x 200|
|Day's Range||261.63 - 269.80|
|52 Week Range||111.35 - 287.32|
|PE Ratio (TTM)||93.65|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Dentsply Sirona (XRAY) reported its 2018 guidance during the company’s 4Q17 and fiscal 2017 earnings results release on March 2, 2018. For fiscal 2018, Dentsply Sirona has an adjusted EPS (earnings per share) guidance range of $2.70–$2.80, representing a growth rate of 8% to 11%. Dentsply Sirona expects to generate flat margins or a decline in its gross margin and operating margin due to currency headwinds, and the negative impact of the reductions in dealer equipment levels.
Although Dentsply Sirona (XRAY) has given a disappointing performance recently, the company is still confident that it can gain a higher market share going forward. The company’s strategic growth plan consists of five key priorities meant to counteract the impact of the significant impairment charges it saw in 2017 (stemming from the merger of Dentsply International and Sirona Dental Systems in February 2016). Below, we’ll discuss why Dentsply Sirona is so confident that it can gain a higher market share in 2018 and 2019.
Dentsply Sirona (XRAY) has a new management team that is working toward a more successful integration, because the company delivered lower-than-expected synergies in 2017 (due to the merger of Dentsply International and Sirona Dental Systems in early 2016). The company has now put in place a new management team that has prioritized five key factors to focus on for the growth of the company (see the previous parts of this series). One of the company’s key priorities is to improve its operational growth through margin improvement.
In outperforming the S&P 500 in the past one, three, five and 10 years, Buffalo Discovery won IBD Best Mutual Funds Awards in both the Growth Fund and Midcap Fund categories.
In 4Q17, Dentsply Sirona (XRAY) started reporting its operations under two segments, after a shift to three segments in fiscal 3Q17. The company had a two segment operational structure prior to 3Q17, but the new two-segment structure has some differences, which we’ll discuss below.
Dentsply Sirona (XRAY) updated its estimates and assumptions during fiscal 2Q17 and underwent an annual impairment test of goodwill. According to company estimates, the goodwill charges associated with some of its technologies segment businesses, including CAD-CAM imaging and its treatment center, came from impairment. The company recorded nearly $1.1 billion in goodwill impairment charges in 2Q17 and $581 million in 4Q17, for a total of ~$1.67 billion in fiscal 2017. Meanwhile, the company undertook an annual impairment assessment of indefinite-lived intangible assets.
Dentsply Sirona (XRAY) is one of the leading dental technology, equipment, and consumables providers in the United States. But the company has been going through some tough times following the merger of Sirona Dental Systems and Dentsply International and the subsequent formation of Dentsply Sirona in February 2016. Dentsply Sirona released its 4Q17 and fiscal 2017 earnings results on March 2, 2018. In this first part of our 14-part series on the company, we’ll take a look at what Wall Street is recommending for Dentsply Sirona now as well as the analyst consensus 12-month target price for the company’s stock.
Investors seeking to increase their exposure to growth should consider companies such as Align Technology and Loma Negra Compañía Industrial Argentina Sociedad Anónima. Analysts are generally optimistic about the futureRead More...
Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics
With the Dow Jones bouncing up and down 300 points a day, interest rates rising, and a trade war brewing, it will not take much to trigger another correction. Here is how five top managers are preparing for the rest of 2018.
Align Technology Inc (NASDAQ:ALGN) is trading with a trailing P/E of 87.8x, which is higher than the industry average of 33.1x. While ALGN might seem like a stock to avoidRead More...
Align Technology’s (ALGN) Invisalign aligners are approved for in-office treatments with GP (general practitioner) dentists and Invisalign-trained orthodontists. Align Technology invested ~$46.7 million in SDC. Align now owns a ~19% stake in SDC.
In fiscal 2017, Align Technology launched a new brand platform for Invisalign called Made to Move. The company reported more than 15 million unique visitors to Invisalign websites all over the world. The Invisalign social media community grew 42% in 2017.
For fiscal 2017, 26% of Invisalign’s clear aligner case starts were for teenagers. In 4Q17 for North American orthodontists, Align witnessed an Invisalign teen patient growth of 47.8%, while international growth was ~64.7%. For the fifth consecutive quarter, Invisalign teenage patient volumes grew more than the adult patient volume.
In recent years, Align Technology (ALGN) has been growing at a fast pace while it executes its strategic priorities around the world. It has laid out these four strategies: international expansion, orthodontist utilization expansion, GP (general practitioner) dentist treat and refer, and patient demand and conversion. In 2018, Align Technology plans to continue to focus on these four growth strategies.